

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jan Weber et al.  
Application No.: Unassigned  
Date Filed: Filed herewith  
Title: MEDICAL ARTICLES HAVING REGIONS WITH POLYELECTROLYTE MULTILAYER  
COATINGS FOR REGULATING DRUG RELEASE  
Group Art Unit: Unassigned  
Examiner.: Unassigned  
Atty. Docket: 03-237

---

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Patent Application  
Commissioner For Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

SIR:

In accordance with 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §§1.97 and 1.98, the references listed on attached Form PTO/SB/08 and/or subsequently identified herein, are being submitted herewith for consideration by the United States Patent and Trademark Office.

I. COPIES

- a. ☒ A legible copy of (i) each U.S. and foreign patents; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed, is included herewith.
- b. ☐ Any patents, publications or other information which are listed on PTO/SB/08 which are not enclosed herewith were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. §120:

U.S. Serial Number

U.S. Filing Date

II. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

- a. ☒ Except as may be indicated below in (b) of this section, all of the patents, publications or other information are in the English language (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

III. ☐ CROSS REFERENCE TO RELATED APPLICATION(S)

The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this (these) applications to the Examiner's attention, Applicant(s) does(do) not waive the confidentiality provisions of 35 U.S.C. §122.

Serial No.

Filing Date

Art Unit


**FEES**

- IV. ☒ **THIS IDS IS BEING FILED UNDER 37 C.F.R. §1.97(b):** (check one box)
- a. ☒ within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. §1.97(b)(1)). No fee or statement is required.
  - b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. §1.97(b)(2)). No fee or statement is required.
  - c. ☐ before the mailing date of a first Office Action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required.
  - d. ☐ before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- V. ☐ **THIS IDS IS BEING FILED UNDER 37 C.F.R. §1.97(c):** (check one box)  
before the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (See 37 C.F.R. §1.97(c)).
- a. ☐ No statement; therefore, charge deposit account 50-1047 the fee set forth in 37 C.F.R. §1.17(p).
  - b. ☐ See the statement below. No fee is required.
- VI. ☐ **THIS IDS IS BEING FILED UNDER 37 C.F.R. §1.97(d):**  
on or before payment of the issue fee and is accompanied by the following:
- 1) a statement under 37 C.F.R. §1.97(e) as provided below; and
  - 2) charge deposit account 50-1047 the petition fee set forth in §1.17(p).
- VII. ☐ **STATEMENT UNDER 37 C.F.R. §1.97(e)** (check only one box, if applicable)  
The undersigned hereby states that
- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of IDS; or
  - b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and to knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement, or
  - c. ☐ some of the items of information contained in the IDS were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.
- VIII. **PAYMENT OF FEES**
- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the above-identified fee(s).
  - ☐ Please charge Deposit Account No. 50-1047 in the amount of \$180.00 for the above-indicated fee(s).
  - ☒ If Applicant has overlooked any additional fees, or if any overpayment has been made, the Commissioner is hereby authorized to credit or debit Deposit Account 50-1047.
  - ☐ Two Copies of this paper are attached for Deposit Account charges and debits.

It is Applicant(s)' opinion that the claims presently on file patently distinguish the present invention from each of these references. The above references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in a combination, to a person of ordinary skill in the art.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 50-1047.

Respectfully submitted,



Keum J. Park  
Attorney for Applicant(s)  
Reg. No. 42,059  
Tel. 908-518-7700  
Fax 908-518-7795

MAYER FORTKORT & WILLIAMS  
Customer Number 27774

Enclosures:

☒  
☒  
☐  
☐


PTO/SB/08  
References (US Patents/Patent Publications Omitted)  
Foreign Search Report  
Other:

### Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited with sufficient postage  
with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 on

3/19/04

and is addressed to Mail Stop Patent Application, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450.



Signature of Person Mailing Correspondence

Marjorie Scariati  
Typed or Printed Name of Person Mailing Certificate

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Jan Weber et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	03-237
Sheet	1	of	1		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>12</sup>Unique hour designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Jan Weber et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	03-237
Sheet	2	of	2		

OTHER PRIOR ART—NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A1	CHUNG, A.J. AND RUBNER, M.F., Methods of Loading and Releasing Low Molecular Weight Cationic Molecules in Weak Polyelectrolyte Multilayer Films, <i>Langmuir</i> 2002, 18, 1176-1183.	
	A2	FRANK CARUSO et al., Microencapsulation of Uncharged Low Molecular Weight Organic Materials by Polyelectrolyte Multilayer Self-assembly, <i>Langmuir</i> 2000, 16, 8932-8936	
	A3	GI-RA, YI et al., Ordered Macroporous Particles by Colloidal Templating, <i>Chem. Mater.</i> 2001, 13, 2613-2618	
	A4	SINGH, R.S., GRIMES, C.A., Dickey, E.C. Fabrication of nanoporous TiO <sub>2</sub> films through Bernard-Marangoni convection, <i>Materials Resources Innovations</i> , 2002, 5:178-184	
	A5	CHAN, V.Z.-H et al. Ordered Bicontinuous Nanoporous and Nanorelief Ceramic Films from Self Assembling Polymer Precursors, <i>Science</i> , Nov 26, 1999, v286, i5445, p1716-1719	
	A6	SHCHUKIN, D.G. et al., Micron-Scale Hollow Polyelectrolyte Capsules with Nanosized Magnetic Fe <sub>3</sub> O <sub>4</sub> Inside, <i>Materials Letters</i> 57, 1743-1747, 2003.	
	A7	RADTCHENKO, I.L. et al., A Novel Method for Encapsulation of Poorly Water-soluble Drugs: Precipitation in Polyelectrolyte Multilayer Shells, <i>International Journal of Pharmaceutics</i> , 242, 219-223 (2002).	
	A8	RADTCHENKO, I.L. et al., Assembly of Alternated Multivalent Ion/Polyelectrolyte Layers on Colloidal Particles. Stability of the Multilayers and Encapsulation of Macromolecules into Polyelectrolyte Capsules, <i>Journal of Colloid and Interface Science</i> , 230, 272-280 (2000)	
	A9	WHAU, WINKY L. et al., Surface-chemistry technology for microfluidics, <i>J. Micromech. Microeng.</i> 13 (2003) 272-278	
	A10	RADTCHENKO et al., Incorporation of macromolecules into polyelectrolyte micro and nanocapsules via surface controlled precipitation on colloidal particles, <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> 202 (2002) 127-133.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Jan Weber et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	03-237

A11	MOYA, S. et al., Polyelectrolyte multilayer capsules templated on biological cells: core oxidation influences layer chemistry, <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> 183-185 (2001) 27-40.
A12	ANTIPOV, ALEXEI A. ET AL., Polyelectrolyte multilayer capsule permeability control, <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> 198-200 (2002) 535-541
A13	QIU, XINGPING et al., Studies on the Drug Release Properties of Polysaccharide Multilayers Encapsulated Ibuprofen Microparticles, <i>Langmuir</i> 2001, 17, 5375-5380
A14	ANTIPOV, ALEXEI A. et al., Sustained Release Properties of Polyelectrolyte Multilayer Capsules, <i>J. Phys. Chem. B</i> 2001, 105, 2281-2284, October 27, 2000
A15	<a href="http://www.bmed.mcgill.ca/tabrizian/People_pages/Benjamin2.htm#cCOMMUNICATIONS">http://www.bmed.mcgill.ca/tabrizian/People_pages/Benjamin2.htm#cCOMMUNICATIONS</a> , THIERRY, BENJAMIN, Development of new strategies for endovascular revascularization procedures, 1-7, date unknown but before the filing of this application
A16	<a href="http://people.ccmr.cornell.edu/~uli/Pages/meso-syn.html">http://people.ccmr.cornell.edu/~uli/Pages/meso-syn.html</a> , Wiesner Research Group, Synthesis of Mesoporous Materials, 1-2, date unknown but before the filing of this application
A17	<a href="https://engineering.purdue.edu/BME/Seminars/2003/july_14_html">https://engineering.purdue.edu/BME/Seminars/2003/july_14_html</a> , Graduate Seminar, Stent coating for drug delivery: Coating polymeric micelles using polyelectrolytes Purdue University Biomedical Engineering Seminar, 2003, 1-2, July 14, 2003
A18	<a href="http://www.ccmr.cornell.edu/~uli/Pages/mesoporous.html">http://www.ccmr.cornell.edu/~uli/Pages/mesoporous.html</a> , Wiesner Research Group, Mesoporous Materials Through Self-Esteem, 1-2, date unknown but before the filing of this application
A19	<a href="http://www.hmi.de/people/chemseddine/group.htm">http://www.hmi.de/people/chemseddine/group.htm</a> , 1-3, date unknown but before the filing of this application
A20	<a href="http://web.mit.edu/newsoffice/nr/1999/gyroid.html">http://web.mit.edu/newsoffice/nr/1999/gyroid.html</a> , MIT researcher's intricate ceramic nanostructures have many potential uses, MIT News, 1-3, November 25, 1999
A21	<a href="https://engineering.purdue.edu/ChE/Nano/NanoChmE/NSE_Topical_2001/SynthesisandCharacterizationofNovelNanoporousMaterials2.htm">https://engineering.purdue.edu/ChE/Nano/NanoChmE/NSE_Topical_2001/SynthesisandCharacterizationofNovelNanoporousMaterials2.htm</a> , 2001, pages 1-8
A22	DINH, NAM et al., University of Santa Barbara, Magnetic Drug Targeting: A novel use of magnetic fields and magnetic particles to deliver therapeutic drugs at the desired time in the correct dosage to the correct site in the human body, pp 1-9, date unknown but before the filing of this application

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>12</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Jan Weber et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	4	of	4	Attorney Docket Number	03-237

	A23	BERRY, CATHERINE C. et al., Potential Drug-Cell Delivery Routes Using Magnetic Nanoparticles, Centre for Cell Engineering, Glasgow University, European Cells and Materials Vol. 6 Suppl. 2, 2003 p 29	
	A24	<a href="http://www2.latech.edu/~ylvov/research/research.htm">http://www2.latech.edu/~ylvov/research/research.htm</a> , LVOV, YURI M., Nanofabrication of ordered multilayers by alternate absorption of polyions, nanoparticles and proteins: From planar films to microtemplates, Institute for Micromanufacturing, LaTech, Ruston, LA 71272, pp. 1-13, date unknown but before the filing of this application.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>12</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.